6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000019090
2015/11/0401/11/2015Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen waterReduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water - Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease Parkinson's diseasereduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks
hydrogen water 500ml(Suisosui 7.0) 16weeks
Juntendo University Koshigaya HospitalNULLComplete: follow-up complete20years-old80years-oldMale and Female45Not selectedJapan
2NCT01892176
(ClinicalTrials.gov)
June 201230/6/2013Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseEffects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseParkinson DiseaseDietary Supplement: coenzyme q10National University Hospital, SingaporeNULLCompleted21 MonthsN/ABoth20Phase 2/Phase 3Singapore
3NCT00740714
(ClinicalTrials.gov)
December 200822/8/2008Effects of Coenzyme Q10 (CoQ) in Parkinson DiseaseEffects of Coenzyme Q10 in Parkinson Disease - Phase IIIParkinson DiseaseDrug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin EWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterTerminated30 YearsN/AAll600Phase 3United States;Canada
4NCT00180037
(ClinicalTrials.gov)
September 20039/9/2005Coenzyme Q10 as a Symptomatic Treatment in Parkinson's DiseaseMulticenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: PlaceboTechnische Universität DresdenDeutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad HomburgCompleted40 Years75 YearsBoth132Phase 3Germany
5NCT00004731
(ClinicalTrials.gov)
September 199825/2/2000Parkinson's Disease Treatment With Coenzyme Q10Effects of Coenzyme Q10 in Early Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10National Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted30 YearsN/ABothPhase 2United States